Brief: Zydus Lifesciences Enters Settlement Agreement With Astellas Over Myrbetriq
12/02/2026 03:02
Feb 12 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS: ZYDUS LIFESCIENCES - ENTERS SETTLEMENT AGREEMENT WITH ASTELLAS OVER MYRBETRIQ ZYDUS LIFESCIENCES - TO PAY ASTELLAS USD 120 MILLION ZYDUS LIFESCIENCES - TO PAY LICENSING FEE ON GENERIC MIRABEGRON ZYDUS LIFESCIENCES - SETTLEMENT CONCLUDES LITIGATIONS, ZYDUS TO MARKET GENERIC MIRABEGRON Source text: ID:nBSE4lWKCb Further company coverage: ZYDU.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)